Definium Therapeutics Inc (DFTX)

NASD · Healthcare · Biotechnology · USA

Definium Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Definium Therapeutics creates drug candidates targeting brain health conditions in late-stage clinical trials. Its primary focus is DT120, a modified version of lysergide for treating generalized anxiety disorder and major depressive disorder. The company also develops DT402, a specialized form of R-enantiomer MDMA intended to address autism spectrum disorder.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Definium Therapeutics Inc stock.

Our verdict on DFTX

Not valued: We cannot value this company yet.

ETFs with the most weight in DFTX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than DFTX in Biotechnology

129 more in this industry show a wider margin of safety.

Is DFTX undervalued or overvalued?

We do not publish a verdict on DFTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of DFTX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.